Table I.
Correlation between methylation of RUNX3 gene promoter and clinicopathological characteristics [n (%)].
| Clinical data | N | Methylation | Non-methylation | χ2 | P-value |
|---|---|---|---|---|---|
| Gender | |||||
| Male | 36 | 14 (38.9) | 22 (61.1) | ||
| Female | 22 | 12 (54.5) | 10 (45.5) | 1.353 | 0.245 |
| Age | |||||
| <60 years | 34 | 15 (41.1) | 18 (55.9) | ||
| ≥60 years | 24 | 11 (45.8) | 14 (54.2) | 0.017 | 0.897 |
| Pathological type | |||||
| Squamous cell carcinoma | 26 | 13 (50.0) | 13 (50.0) | ||
| Adenocarcinoma | 32 | 13 (40.6) | 19 (59.4) | 0.510 | 0.475 |
| Clinical staging | |||||
| Stage I+II | 25 | 7 (28.0) | 18 (72.0) | ||
| Stage III+IV | 33 | 19 (57.6) | 14 (42.4) | 5.031 | 0.025 |
| Lymph node metastasis | |||||
| No | 34 | 7 (29.2) | 17 (70.8) | ||
| Yes | 24 | 19 (55.9) | 15 (44.1) | 4.060 | 0.044 |
| Differentiation degree | |||||
| Poorly differentiated | 23 | 16 (69.6) | 7 (30.4) | ||
| Moderately and highly differentiated | 35 | 10 (28.6) | 25 (71.4) | 9.431 | 0.002 |
| Smoking history | |||||
| No | 16 | 10 (62.5) | 6 (37.5) | ||
| Yes | 42 | 16 (38.1) | 26 (61.9) | 2.790 | 0.095 |